Systematic review explores the effects of ivermectin in preventing and treating COVID-19

NewsGuard 100/100 Score

Ivermectin, a drug used to treat parasites such as scabies in humans and intestinal helminths in cattle, was screened in 2020 for activity against COVID-19. Laboratory tests suggested a weak effect on the SARS-CoV-2 virus in a test tube but did not seem feasible in humans as the doses needed would be large. However, small early trials suggested large effects on mortality, and this has led to some advocacy groups lobbying for its widespread introduction worldwide.

Researchers from the CEOsys project collaborated with the LSTM-based Cochrane Infectious Disease Group (CIDG) to carry out a systematic review, published today in the Cochrane Library, to explore the effects of ivermectin in preventing and treating COVID-19 infection.

The review authors included 14 randomized controlled trials with 1678 participants. Treatment of mild to moderate COVID-19 patients was investigated in 13 studies comparing ivermectin with placebo or with no treatment in addition to comparable usual care in the study arms. Only one study investigated prevention of SARS-CoV-2 infection and compared ivermectin to no treatment. The review looked at the effects of ivermectin on the number of deaths, whether the patient's condition worsened or improved, and unwanted effects.

The Cochrane review cannot confirm whether ivermectin (administered in hospital or as an outpatient) compared with placebo or usual care, leads to more or fewer deaths after one month, whether it improves or worsens patients' condition, increases or decreases unwanted side effects, nor whether it increases or reduces negative COVID-19 tests 7 days after treatment. Likewise, the review cannot confirm whether or not ivermectin prevents SARS-CoV-2 infection or reduces number of deaths after high-risk exposure.

Main authors on the review, Maria Popp and Stephanie Weibel said: "The lack of good quality evidence on efficacy and safety of ivermectin arises from a study pool that consists mainly of small, insufficiently powered RCTs with overall limited quality regarding study design, conduct and reporting. Current evidence does not support using ivermectin for treating or preventing of COVID-19 unless they are part of well-designed randomized trials."

This is a great review from an experienced team. The hype around ivermectin is driven by some studies where the effect size for ivermectin is frankly not credible, and this has driven the conclusions in other reviews. The study with a huge effect has now been retracted as fake. Careful appraisal is the cornerstone of Cochrane's work, and with such extreme public demands for a drug to work during the pandemic, it remains vital that we hold onto our scientific principles to guide care."

Paul Garner, CIDG Co-ordinating Editor

Journal reference:

Popp, M., et al. (2021) Ivermectin for preventing and treating COVID‐19. Cochrane Database of Systematic Reviews.


  1. Charles Chelliah Charles Chelliah Australia says:

    If the Covid vaccines can be administered on people (based on a technology that was never used in human before) without having the clinical trials done to know the short term and long term effects, then why shouldn't a medicine that has been used for many decades and have enough information on effects on human cannot be tried at least as a precautionary measure against Covid?

  2. Leo Goldstein Leo Goldstein United States says:

    This is a shameful pandering to governments and other institutions funding Cochrane. The authors cherry picked 11 out of dozens of peer-reviewed papers. The authors have also ignored the practical experience.

  3. Sandra Vardine Sandra Vardine United States says:

    Far many papers worldwide that contradict these findings.  One has to wonder what their motive was.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.